The Phase IV B2219 trial was the first prospective study specifically designed to assess the efficacy of incretin-based therapy versus insulin in the management of pasireotide-associated hyperglycemia that is not fully controlled despite treatment with metformin or other non-incretin-based oral antidiabetic drugs (OADs) in participants with acromegaly or Cushing’s disease (21). This evidence concerns the gene INS and Hyperglycemia.